Envoy Medical, Inc. (COCH)
(Delayed Data from NSDQ)
$1.51 USD
+0.03 (2.03%)
Updated Aug 6, 2025 03:57 PM ET
After-Market: $1.49 -0.02 (-1.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COCH 1.51 +0.03(2.03%)
Will COCH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COCH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COCH
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) Reports Q3 Loss, Lags Revenue Estimates
COCH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orthofix (OFIX) Q3 Earnings Surpass Estimates
Masimo (MASI) Q3 Earnings and Revenues Top Estimates
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
Other News for COCH
Envoy Medical GAAP EPS of -$0.32, revenue of $0.08M
Envoy Medical Reports on Second Quarter 2025 Results | COCH Stock News
Envoy Medical Expands Patent Portfolio with New Issuances in the United States | COCH Stock News
Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia | COCH Stock News
New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, ...